Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Gains from Investment Securities (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Gains from Investment Securities data on record, last reported at -$10864.0 in Q3 2025.

  • For Q3 2025, Gains from Investment Securities rose 96.84% year-over-year to -$10864.0; the TTM value through Sep 2025 reached -$1.1 million, down 428.55%, while the annual FY2024 figure was $3.2 million, 22.46% up from the prior year.
  • Gains from Investment Securities reached -$10864.0 in Q3 2025 per GANX's latest filing, up from -$673289.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $3.2 million in Q4 2024 and bottomed at -$673289.0 in Q2 2025.
  • Average Gains from Investment Securities over 5 years is $143715.1, with a median of $8175.0 recorded in 2021.
  • Peak YoY movement for Gains from Investment Securities: crashed 1451.51% in 2021, then soared 3530.58% in 2022.
  • A 5-year view of Gains from Investment Securities shows it stood at -$403938.0 in 2021, then skyrocketed by 84.41% to -$62993.0 in 2022, then crashed by 276.92% to -$237434.0 in 2023, then surged by 1427.71% to $3.2 million in 2024, then crashed by 100.34% to -$10864.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were -$10864.0 in Q3 2025, -$673289.0 in Q2 2025, and -$109591.0 in Q1 2025.